• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Cannabis Market
    Cannabis News
    Cannabis Stocks
    • Cannabis Market
    • Cannabis News
    • Cannabis Stocks

    Aurora Cannabis Announces $50,625,000 Bought Deal Private Placement of Units

    Pia Rivera
    Jan. 25, 2017 08:40AM PST
    Cannabis Investing News

    Aurora Cannabis (TSXV: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) announced an agreement with a syndicate of underwriters led by Canaccord Genuity Corp. to purchase, on a bought deal private placement basis 22,500,000 units of the Company at a price of $2.25 per Unit. Closing of the Offering is expected to occur on or about …

    Aurora Cannabis (TSXV: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) announced an agreement with a syndicate of underwriters led by Canaccord Genuity Corp. to purchase, on a bought deal private placement basis 22,500,000 units of the Company at a price of $2.25 per Unit. Closing of the Offering is expected to occur on or about February 23, 2017.
    As quoted in the press release:

    Each Unit will be comprised of one common share of the Company (a “Common Share”) and half of one Common Share purchase warrant (each whole Common Share purchase warrant, a “Warrant”). Each Warrant will be exercisable to acquire one Common Share (a “Warrant Share”) for a period of two years following the closing date of the Offering at an exercise price of $3.00 per Warrant Share, subject to adjustment in certain events. The Warrants will be subject to a forced exercise provision if the Company’s daily volume weighted average share price on the TSX Venture Exchange (or such other stock exchange the Company may be trading on) is greater than $4.50 for 10 consecutive trading days. Net proceeds from the Offering will be used primarily towards the Company’s strategic growth initiatives including its planned facility expansion, and for general working capital purposes.

    Click here for the full press release.

    bought deal private placementprivate placement
    The Conversation (2)
    Matthew Mitchell
    Matthew Mitchell
    30 Jan, 2017
    What is the best ground floor company that's going to deserve attention in Canada in penny stocks do you know
    0 Replies Hide replies
    Show More Replies
    Matthew Mitchell
    Matthew Mitchell
    30 Jan, 2017
    What is the best ground floor company that's going to deserve attention in Canada in penny stocks do you know
    0 Replies Hide replies
    Show More Replies

    Go Deeper

    AI Powered

    Aurora Cannabis Acquires MedReleaf Australia

    Aurora Cannabis Announces Settlement of Patent Litigation

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×